Mpox Outbreak Emerges in Anchorage, Alaska, as Cases Rise Without Recent Travel

Anchorage Health Officials Track New Mpox Cluster

Four new cases of mpox have been identified in Anchorage, prompting a state-wide health advisory as officials work to determine the source of the infections.

The cases represent the highest annual total for Alaska since 2022, when a global outbreak led to five diagnosed infections, according to the Anchorage Daily News.

This development marks a shift in local transmission patterns. Unlike previous instances where travel to other regions was the primary factor, the individuals currently infected reported no out-of-state travel during the month before their symptoms began. Dr. Joe McLaughlin, the state epidemiologist, confirmed the fourth case was reported to health officials on Thursday.

Transmission Questions and Clinical Signs

State health officials and representatives from the U.S. Centers for Disease Control and Prevention are currently investigating potential links between the patients. While two of the individuals are partners, it remains unclear if the other cases share a direct connection.

Dr. Randi Rollins, a CDC epidemiologist assisting the Alaska Department of Health, noted that the lack of travel history does not definitively prove the virus is spreading locally, suggesting the patients could be at the end of a transmission chain initiated by a traveler.

Mpox typically presents with an initial phase of flu-like symptoms, including fever, chills, fatigue, headaches, and swollen lymph nodes. This is followed by the development of firm or tender lesions. Because the virus remains infectious until every lesion has completely healed—a process that can take two to four weeks—patients are currently isolating to prevent further spread.

New outbreak of mpox in Anchorage prompts advisory from state health officials — Photo: europesays.com

National Trends and Vaccine Guidance

The current situation in Alaska aligns with a broader national trend. After a period of relative decline following the 2022-2023 global outbreak, infections began trending upward in March 2026.

The virus circulating now is identified as clade I, which is genetically distinct from the clade II variety that dominated the 2022 wave. While clade I has historically been linked to more severe outcomes in Central Africa, health officials report that the current strain does not appear to be particularly deadly.

State authorities are encouraging vaccination for those at higher risk, including men who have sex with men, individuals with known exposure to the virus, and healthcare workers. The JYNNEOS vaccine, which received FDA approval in 2019, remains the primary tool for protection. According to state immunization records, 851 Alaskans have received the first dose since 2022, with 604 completing the full two-dose regimen.

Vaccination can still be beneficial shortly after exposure. Dr. Rollins indicated that receiving the vaccine within four days of contact is ideal, though it may still reduce disease severity if administered within 14 days.

Monitoring Borealpox in Alaska

Alongside the mpox response, officials are continuing to monitor a related, rarer viral disease known as borealpox, formerly referred to as Alaskapox. Two cases have been diagnosed this year, bringing the global total to nine since the virus was first identified in Fairbanks in 2015. Unlike mpox, there is currently no vaccine available for borealpox.

The disease primarily circulates among small mammals, particularly red-backed voles, which are common across Alaska. While most cases have been mild, a man in his 60s with a compromised immune system died from a genetically distinct strain of the virus in January 2024. Health officials are currently investigating how household pets may be acting as intermediaries between the voles and human infections.